Citadel CEO Ken Griffin is a Republican who has been outspokenly critical of some of President Trump’s policies. Griffin sat down with Editor in Chief Emma Tucker. Photo: Uncredited The snowballing ...

The S&P 500 on Friday rose 1.97%, recording its best day since May, as it rebounded from a week of dramatic selling triggered yet again by the AI boom and what it will mean for the economy, companies ...

This week’s stock selloff was a reminder that even a shift in market leadership has its limits, as it failed to shield investors from a sharp pullback in technology names that brought echoes of the ...

Bitcoin rebounds after testing an intraday low at $60,000 amid persistent retail investor exit. Ethereum shows subtle signs of recovery, but ETFs outflows limit upside. XRP gains by over 10% on Friday ...

The great violin virtuoso Itzhak Perlman posted a 1964 video on social media this week in which he is seen at age 18 playing a violin concerto. It’s a striking clip not only for Perlman’s mastery of ...

Gold and silver prices clawed back ground on Tuesday after suffering a historic selloff. International mining stocks and ETFs also rallied in early trading. Investor intentions in precious metals have ...

January arrives with fresh resolutions, and for many people, weight loss tops the list. In this context, medications like Ozempic and Mounjaro have surged in popularity. They’ve helped shift an ...

Forbes contributors publish independent expert analyses and insights. An award-winning reporter writing about stargazing and the night sky. This voice experience is generated by AI. Learn more. This ...

Stock indexes reject their recent highs as trade uncertainty returns. Still, dip buyers are showing resilience, taking stock indexes back higher after a rough post-MLK Day session open. Exploring ...

"I don't think anyone's made this connection between the surface fluid pattern and the interior properties of these planets." When you purchase through links on our site, we may earn an affiliate ...

Biotech IPOs hit lowest level in over a decade in 2025 Investors focus on biotechs with mature pipelines and positive trial data Lower interest rates and capital inflows expected to boost sector Jan ...